Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1636 to 1650 of 2188 results for guidelines

  1. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA195

  2. Pneumonia in adults: diagnosis and management (CG191)

    This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).

    Withdrawn guideline

  3. Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)

    This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).

    Withdrawn guideline

  4. Depression in adults: recognition and management (CG90)

    This guideline has been updated and replaced by NICE guideline on depression in adults: treatment and management (NG222).

    Withdrawn guideline

  5. Head injury: assessment and early management (CG176)

    This guideline has been updated and replaced by the NICE guideline on head injury: assessment and management (NG232).

    Withdrawn guideline

  6. Pneumonia (community-acquired): antimicrobial prescribing (NG138)

    This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).

    Withdrawn guideline

  7. Glitazones in the treatment of type 2 diabetes (TA63)

    This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).

    Withdrawn guidance

  8. Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)

    This guideline has been updated and replaced by the NICE guideline on spinal metastases and metastatic spinal cord compression (NG234).

    Withdrawn guideline

  9. The clinical effectiveness and cost effectiveness of tension-free vaginal tape for stress incontinence (TA56)

    This guidance has been updated and replaced by NICE guideline CG40. [Replaced by NICE guideline CG171 (September 2013)] 

    Withdrawn guidance

  10. Stop smoking interventions and services (NG92)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  11. Smoking prevention in schools (PH23)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  12. Smoking: stopping in pregnancy and after childbirth (PH26)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  13. Smoking: harm reduction (PH45)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  14. Smoking: acute, maternity and mental health services (PH48)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  15. Smoking: workplace interventions (PH5)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline